Comparison of Premixed Insulins Aspart 30, Aspart 70 and Aspart on Postprandial Lipids

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study is to investigate meal-related treatment with either premixed Insulin Aspart 30, Aspart 70 and Aspart with regard to postprandial glucose, triglyceride and free fatty acids excursions after a standard breakfast and lunch.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Graz
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin aspart, insulin aspart protamine drug combination 30:70; Insulin degludec, insulin aspart drug combination; Insulin, Globin Zinc; Insulin, Isophane; Insulin, Long-Acting

Criteria

Inclusion Criteria:

• Type-II Diabetes

• BMI > 27 kg/m2

• age 35 to 75 years

• HbA1c < 8.5%

• informed consent

• treatment with pre-mixed insulin

• stabile dose of insulin for at least 4 weeks

Exclusion Criteria:

• Type-I Diabetes mellitus

• HbA1c > 8.5 %

• Serum Creatinine > 1.7 mg/dl

• Alaninaminotranferase or Aspartataminotransferase > 3x Upper Limit of Normal

• treatment with sulfonylurea or gliptins

• treatment with glitazones

• manifest clinical infections

• treatment with glucocorticoids or antipsychotic drugs

• psychiatric diseases

• alcohol abuse

• myocardial infarction or stroke within the previous 3 months

• surgery within the previous 3 months